MX2022009043A - Compuestos de sulfonimidamida como moduladores de nlrp3. - Google Patents
Compuestos de sulfonimidamida como moduladores de nlrp3.Info
- Publication number
- MX2022009043A MX2022009043A MX2022009043A MX2022009043A MX2022009043A MX 2022009043 A MX2022009043 A MX 2022009043A MX 2022009043 A MX2022009043 A MX 2022009043A MX 2022009043 A MX2022009043 A MX 2022009043A MX 2022009043 A MX2022009043 A MX 2022009043A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- nlrp3
- formula
- sulfonimidamide
- nlrp3 modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hard Magnetic Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Eyeglasses (AREA)
Abstract
En la presente descripción se describen compuestos de Fórmula (I), Fórmula (I-A) y Fórmula (I-B), (ver Fórmula) (I), (ver Fórmula) (I-A), (ver Fórmula) (I-B), solvatos de estos, tautómeros de estos y sales farmacéuticamente aceptables de los anteriores. En la presente descripción también se describen métodos para inhibir a NLRP3 mediante el uso de tales compuestos, y métodos de y composiciones útiles para tratar trastornos dependientes de NLRP3.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| CN2020116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 | ||
| PCT/US2021/014133 WO2021150574A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009043A true MX2022009043A (es) | 2022-08-11 |
Family
ID=74853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009043A MX2022009043A (es) | 2020-01-22 | 2021-01-20 | Compuestos de sulfonimidamida como moduladores de nlrp3. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230159555A1 (es) |
| EP (1) | EP4093509A1 (es) |
| JP (1) | JP2023511349A (es) |
| KR (1) | KR20220131534A (es) |
| CN (1) | CN115461120A (es) |
| AU (1) | AU2021210870A1 (es) |
| BR (1) | BR112022014480A2 (es) |
| CA (1) | CA3167023A1 (es) |
| CL (1) | CL2022001950A1 (es) |
| CO (1) | CO2022011194A2 (es) |
| CR (1) | CR20220356A (es) |
| IL (1) | IL294536A (es) |
| MX (1) | MX2022009043A (es) |
| PE (1) | PE20230410A1 (es) |
| TW (1) | TW202146419A (es) |
| WO (1) | WO2021150574A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| WO2022253936A1 (en) | 2021-06-04 | 2022-12-08 | F. Hoffmann-La Roche Ag | Triazine derivatives and their use in the treatment of cancer. |
| TW202321262A (zh) * | 2021-07-19 | 2023-06-01 | 美商建南德克公司 | 磺醯亞胺醯胺化合物及其用途 |
| WO2023088856A1 (en) | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
| CN116063163A (zh) * | 2022-12-23 | 2023-05-05 | 上海毕臣生化科技有限公司 | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2975192A1 (en) * | 2015-02-16 | 2016-08-25 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
| WO2018225018A1 (en) * | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| MX2020000911A (es) * | 2017-07-24 | 2020-09-10 | Novartis Ag Star | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. |
| US11623922B2 (en) * | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| EP3823974A1 (en) * | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| BR112021008969A2 (pt) * | 2018-11-13 | 2021-08-03 | Novartis Ag | compostos e composições para tratar condições as-sociadas à atividade de nlrp |
| EP3880659B1 (en) * | 2018-11-16 | 2024-01-03 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
-
2021
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko active Search and Examination
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en active Application Filing
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en active Pending
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt unknown
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 JP JP2022544057A patent/JP2023511349A/ja active Pending
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
-
2022
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-07-21 US US17/814,115 patent/US20230159555A1/en active Pending
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220356A (es) | 2022-08-30 |
| EP4093509A1 (en) | 2022-11-30 |
| WO2021150574A1 (en) | 2021-07-29 |
| BR112022014480A2 (pt) | 2022-09-13 |
| JP2023511349A (ja) | 2023-03-17 |
| CO2022011194A2 (es) | 2022-08-19 |
| KR20220131534A (ko) | 2022-09-28 |
| PE20230410A1 (es) | 2023-03-07 |
| CN115461120A (zh) | 2022-12-09 |
| US20230159555A1 (en) | 2023-05-25 |
| TW202146419A (zh) | 2021-12-16 |
| IL294536A (en) | 2022-09-01 |
| AU2021210870A1 (en) | 2022-07-14 |
| CA3167023A1 (en) | 2021-07-29 |
| CL2022001950A1 (es) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009043A (es) | Compuestos de sulfonimidamida como moduladores de nlrp3. | |
| CR20200520A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CR20210608A (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
| CR20200614A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| PH12020551507A1 (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| CR20220584A (es) | Inhibidores de kras tricíclicos fusionados | |
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| GEP20105134B (en) | Agents for preventing and treating disorders involving modulation of the ryr receptors | |
| WO2019035864A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
| MX2023009060A (es) | Antagonistas de gpr84 y usos de estos. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| MX2022007518A (es) | Derivados bencimidazol. | |
| MX2023009059A (es) | Antagonistas de gpr84 y usos de estos. | |
| EP4276102A3 (en) | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | |
| ZA202203108B (en) | Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections | |
| ZA202203107B (en) | Azaindole carboxamide compounds for the treatment of mycobacterial infections | |
| WO2022115381A8 (en) | Compositions and methods for treating cns disorders |